PENSACOLA, FL--(NewMediaWire - Sep 14, 2015)
- Gear International,
Inc. (OTC
PINK: GEAR) is pleased to announce
that Cannaworx, a GEAR portfolio company, has
partnered with Innovative Extractions to acquire cutting edge
extraction systems in order to develop proprietary cannabis and
hemp based products. The new system allows for the extraction of
multiple plant materials concurrently while keeping the outputs
isolated. These "cannabinoid-specific" formulas will serve specific
patient needs more effectively by addressing the primary symptoms
associated with them.
"While Cannaworx does not claim cannabis to be a cure for cancer
and the many other health challenges of our day, we can provide
patient testimony and actual evidence that cannabis has helped
other groups of patients with the same conditions," said Robert F.
Calkin, CEO of Cannaworx, Inc. "We will be conducting efficacy and
safety trials in tandem with doctors in multiple areas of medicine
who all have separate concerns and necessary outcomes in mind. We
intend to modify these formulas to the needs of these patient
groups in hopes that we will be able to help them more effectively
and provide a way for their formulas to be produced."
New Terpene and Cannabinoid Arrays
Dr. Gerry Bedore from Cannaworx works directly with these
patients every day, observing the results of cannabinoid therapy.
"Based on patient response trials, specific cannabinoid and terpene
arrays have reduced the need for opioids in pain management for
severely ill patients, giving the patients improved sleep, improved
appetites, and improved mental dispositions at a minimum. An
improved quality of life is the worst case response we are seeing.
In the best case scenarios, we are seeing patients being healed
from many other deadly diseases. It is time for America to flip the
switches and allow our medical communities to research and work
with cannabinoids."
The list of conditions currently being studied with these
patient groups include: cancers of the lungs, liver, breast, heart,
ovaries, skin, colon, rectal, prostate, blood, metastatic, and
brain cancer. In addition, shingles, gout, obesity, opioid
addiction, ALS, and others.
New Pathways to Healthcare Solutions
The goal of Eagles Nest Health, Wellness and Research Center
(Cannaworx's Northern California research and development,
extraction and farming resource center nestled in the pristine
Klamath River Valley) is to provide a path for doctors and
researchers to obtain cannabinoid arrays specific to their patient
groups and to help them create a tailor made treatment program for
their patients. Our team of scientists works with healthcare
professionals to hone in on the cannabinoid profile that is
effective for each patient's needs. Cannaworx is also helping
healthcare professionals to create protocols for their clinical
trials, grants, papers and studies they will need to present to
their peers when presenting the benefits of cannabinoid therapies
to other doctors across the United States. Dr. Gerry Bedore from
Cannaworx currently is at the forefront of working with doctors
looking to help patients with these diseases.
About Cannaworx, Inc.
As a resource provider, including facilities, equipment,
consulting, product development, research and development,
financing, personnel, and management of all functional areas to the
cannabis and hemp industries, Cannaworx, Inc. brings decades of
experience and know-how to the embryonic cannabis and hemp
industries.
From supporting a growing cultivation and extraction operation
in Northern California to joint venture and business arrangements
in Nevada and Canada, Cannaworx, Inc. is positioning itself for
national and global growth of branded cannabis and hemp products
focused on wellness and the general welfare of its end patients and
customers.
About Gear International, Inc.
Gear International (OTC
PINK: GEAR) is a public company that offers a viable and
often creative funding resource and joint venture opportunities for
companies seeking unconventional funding, hard asset loans,
expansion capital and/or other resources. The objective is to
assist companies that are in a unique position to capitalize on a
current trend or scale their operational business. By providing
timely capital and other resources, the management teams of our
companies can accelerate product launches, expand into new
territories, and often even pioneer an entire new
category. www.gear.international
Forward-Looking Statements
This press release contains statements which may constitute
"forward-looking statements" within the meaning of the Securities
Act of 1933 and the Securities Exchange Act of 1934, as amended by
the Private Securities Litigation Reform Act of 1995. Those
statements include statements regarding the intent, belief or
current expectations of Gear International, Inc. and members of its
management as well as the assumptions on which such statements are
based. Prospective investors are cautioned that any such
forward-looking statements are not guarantees of future performance
and involve risks and uncertainties, and that actual results may
differ materially from those contemplated by such forward-looking
statements. The company undertakes no obligation to update or
revise forward-looking statements to reflect changed assumptions,
the occurrence of unanticipated events or changes to future
operating results.
FEDERAL LEGAL PROHIBITION: THE COMPANY INTENDS TO ENTER,
DIRECTLY OR THROUGH SUBSIDIARY OR AFFILIATED BUSINESS ENTITIES, THE
BUSINESS OF FUNDING RESOURCE PROVIDERS OF FACILITIES, EQUIPMENT,
CONSULTING, PRODUCT DEVELOPMENT, RESEARCH, FINANCING, PERSONNEL,
AND MANAGEMENT TO ENTITIES INVOLVED IN THE MANUFACTURING,
PRODUCING, AND DISTRIBUTION OF A PRODUCT THAT INCLUDES MARIJUANA.
MARIJUANA IS CLASSIFIED FEDERALLY AS A SCHEDULE 1 NARCOTIC. IT IS A
FELONY TO DISTRIBUTE, CULTIVATE OR USE MARIJUANA. IRRESPECTIVE OF
THE LAWS OF THE STATE OF ILLINOIS OR ANY OTHER STATE, THE FEDERAL
GOVERNMENT COULD AT ANY TIME CHOOSE TO PROSECUTE THE COMPANY AND
ITS OWNERS. ANY AND ALL INVESTORS MUST BE WILLING TO BEAR THIS
EXTREME RISK OF PROSECUTION, PENALTY AND IMPRISONMENT.
Investors are cautioned that due to the Company's acquisition of
the right to receive income from companies offering various
services to marijuana farming operations, an investment in this
Company is extraordinarily risky, involving a multiplicity of
extreme risks given the conflict of laws and the potential
consequences of that conflict, including very substantial legal
risk of federal prosecution, penalty and imprisonment, as marijuana
is still classified federally as a Schedule 1 narcotic.
It is a felony, in violation of the Controlled Substances Act,
to distribute, cultivate or use marijuana; and the very
comprehensive federal and international anti-money laundering
statutes, including: Bank Secrecy Act (1970), Money Laundering
Control Act (1986), Anti-Drug Abuse Act of 1988, Annunzio-Wylie
Anti-Money Laundering Act (1992), Money Laundering Suppression Act
(1994), Money Laundering and Financial Crimes Strategy Act (1998),
Uniting and Strengthening America by Providing Appropriate Tools to
Restrict, Intercept and Obstruct Terrorism Act of 2001 (USA Patriot
Act [Title III of the USA Patriot Act is referred to as the
International Money Laundering Abatement and Financial
Anti-Terrorism Act of 2001]), Intelligence Reform & Terrorism
Prevention Act of 2004. At least a portion of these provisions
expressly include restrictions upon the use of the banking system
to transfer the proceeds of such investments, which could be viewed
as money laundering.
These violations are irrespective of the laws of any state, at
any time, despite its current position. The current federal
guidelines are outlined in the Federal Department of Justice
guidelines regarding Marijuana Related Financial Crimes dated
February 14th, 2014, commonly referred to as the Cole
Memorandum: http://www.justice.gov/sites/default/files/oip/legacy/2014/07/23/dag-guidance-2011-for-medical-marijuana-use.pdf....
And more recently, in December 2014, the U.S. House of
Representatives approved H.R. 83 "Consolidated and Further
Continuing Appropriations Act, 2015," defunding the federal war on
medical marijuana. The provision passed the Senate and was signed
by President Obama. Section 538 of the Act prohibits the use of
Department of Justice funds to "prevent [states that legalized the
medicinal use of marijuana] from implementing their own State laws
that authorize the use, distribution, possession, or cultivation of
medical marijuana."
Similarly, in July 2015 the U.S. Senate Committee voted to
prohibit the US Justice Department from interfering in state
medical marijuana laws. Despite these recent reversals in
governmental policies, however, there remains a substantial legal
risk of federal prosecution, penalty, forfeiture and imprisonment,
and for a multitude of potential violations. Additionally, the cost
of assuring compliance and the costs associated with otherwise
normal business transactions, are substantially enhanced by these
circumstances. Risks peculiar to the issuer, also include a very
substantial strategic risk associated with lack of ownership and
consequent lack of control over the subject property and
operations, which lack of ownership and control is mandated by the
laws and regulations of the jurisdiction in which the marijuana is
grown. The risks also include a very substantial economic risk,
including as a consequence of the foregoing recitation of other
legal risks. It is just such risks that that have prevented those
in the industry from securing any financing from other sources.
Nonetheless, the Department of Justice could choose to prosecute
the Operator and its owners, and all those who may be perceived to
have aided and abetted, including the Facilitators and the Real
Estate Owner. Accordingly, there remains a substantial legal risk
of federal prosecution, penalty, forfeiture and imprisonment, and
for a multitude of potential violations. Additionally, the cost of
assuring compliance and the costs associated with otherwise normal
business transactions, are substantially enhanced by these
circumstances. Risks also include a very substantial strategic risk
associated with lack of ownership and consequent lack of control
over the subject property and operations, which lack of ownership
and control is mandated by the laws and regulations of the
jurisdiction in which the marijuana is grown.
The risks also include very substantial economic risks,
including as a consequence of the foregoing recitation of other
risks. It is just such risks that that have prevented the growers
from securing any financing from other sources, over a substantial
period of time. Finally, given the extraordinary return on the
investment, there is even a risk of the financial arrangement being
construed as a "loan," which may, at least arguably, not be exempt
from applicable usury laws, even though this financial arrangement
is not a loan, let alone a conventional loan, but is in the nature
of risk capital financing/provision of services and real estate and
that the contemplated compensation appears to be, and has been
represented by the payors to be commensurate with the multiplicity
and magnitude of the risks, including those as above
identified."
